Key Points {#FPar1}
==========

Tacrolimus is more than 99% associated with erythrocytes. This may result in diminished whole-blood concentrations when hematocrit decreases.The whole-blood to unbound plasma concentration ratios differ with changes in hematocrit and show saturation in the higher range of whole-blood tacrolimus concentrations, which may increase toxicity in these higher concentration ranges.Because of the complicated bio-analytical challenges, hematocrit-corrected whole-blood concentrations may be the most feasible and suitable surrogate for the prediction of clinical outcomes.

Introduction {#Sec1}
============

Since 1996, tacrolimus has been used as an immunosuppressant in solid organ transplantation. Exposure and outcome relationships of tacrolimus have been extensively studied resulting in a worldwide consensus on its therapeutic window \[[@CR1]\]. Nevertheless, there is room for improvement because patients with alleged therapeutic whole-blood concentrations are still at risk of tacrolimus-related toxicity and rejection \[[@CR2]--[@CR6]\]. Tacrolimus extensively binds to red blood cells and blood proteins. As a consequence, tacrolimus whole-blood distribution is strongly affected by hematocrit and protein concentrations, e.g., albumin, lipoproteins, and α~1~-acid glycoprotein \[[@CR7]--[@CR11]\]. While whole-blood concentrations are commonly used for therapeutic drug monitoring, the unbound tacrolimus plasma concentrations might be better related to the toxicity and efficacy of tacrolimus \[[@CR8], [@CR12], [@CR13]\]. In particular, early after heart and lung transplantation, the concentrations of red blood cells and (lipo)proteins show high intra- and interpatient variation \[[@CR14]\]. This may give rise to extreme variability in unbound tacrolimus concentrations in the clinically unstable phase after thoracic organ transplantation. Accordingly, therapeutic drug monitoring of unbound tacrolimus plasma concentrations could improve tacrolimus dosing in unstable thoracic organ recipients.

Studies investigating the unbound tacrolimus plasma concentrations are scarce because the quantification of unbound tacrolimus concentrations is bio-analytically challenging and time consuming \[[@CR7]\]. As such, the relationship between whole-blood and unbound concentrations has not systematically been studied and no pharmacokinetic models to predict the unbound concentrations based on whole-blood concentrations are available at present. Furthermore, a therapeutic range of unbound tacrolimus plasma concentrations is currently lacking for routine therapeutic drug monitoring \[[@CR7]--[@CR9], [@CR15]\].

This study aimed to quantify the pharmacokinetics of whole-blood, total, and unbound plasma tacrolimus in patients early after heart and lung transplantation. With this model, we studied the effect of erythrocyte binding and evaluated whether monitoring based on unbound or total plasma concentrations is feasible as a predictor of clinical outcomes.

Methods {#Sec2}
=======

Data were derived from 30 thoracic organ transplantation patients comprising ten heart and twenty lung transplantation patients in the first six days after transplantation. The accredited Review Board for Human Studies of the University Medical Center Utrecht approved the study (NTR 3912/EudraCT 2012-001909-24).

Patients {#Sec3}
--------

All thoracic organ recipients admitted to the intensive care unit of the University Medical Center Utrecht between June 2013 and March 2015 were considered for inclusion. Inclusion criteria were patients aged older than 18 years who were treated with tacrolimus and provided informed consent. No patients were excluded because of the exclusion criteria: dying within 1 day after admission, known allergies for tacrolimus and macrolides, or retrieving total parenteral nutrition. The immunosuppressive regimen contained tacrolimus, Prograft^®^ (Astellas Pharma Europe, Leiden, The Netherlands), a cell-cycle blocker, an interleukin-2 inhibitor, and corticosteroids. Tacrolimus was dosed orally twice daily starting with 0.1 mg/kg for the lung recipients and 2 mg for the heart recipients on the day of transplantation. Dose adjustments were based on whole-blood tacrolimus concentrations at 6 a.m. (12 h after administration). The therapeutic window ranged from 9 to 15 ng/mL for all patients.

Tacrolimus Analyses {#Sec4}
-------------------

Twelve-hour profiles of unbound and total tacrolimus plasma concentrations together with whole-blood tacrolimus concentrations were analyzed daily from the transplantation date until 6 days after transplantation provided the patients were admitted to the intensive care unit. Blood samples were collected between 6 p.m. and 6 a.m. Blood samples for the measurement of unbound and total tacrolimus plasma concentrations were drawn at 0, 2 (or 3 in the case of cystic fibrosis), 6, and 12 hours after administration of tacrolimus and collected in vacutainer tubes of 10 mL containing ethylenediaminetetraacetic acid. Blood samples were immediately centrifuged at the laboratory of the University Medical Center Utrecht. Then, plasma samples were stored at − 80 °C and were analyzed at the end of the study. Analyses of unbound tacrolimus plasma concentrations were performed as described by Stienstra et al. \[[@CR16]\]. The method was validated over a linear range of 1.00--200 pg/mL for unbound tacrolimus concentrations in plasma and 100--3200 pg/mL for total plasma concentrations. The lower limit of quantification was 1.00 pg/mL in ultrafiltrate and 100 pg/mL in plasma. The inaccuracy and imprecision for the determination of unbound tacrolimus concentrations in ultrafiltrate and plasma showed a maximum coefficient of variation of 11.7% and a maximum bias of 3.8%.

Analyses of whole-blood tacrolimus was conducted using high-performance liquid chromatography-tandem mass spectrometry (Thermo Fisher Scientific, Eindhoven, The Netherlands) with a lower limit of quantification of 0.5 ng/mL and an intraday imprecision of \< 5%. The high-performance liquid chromatography-tandem mass spectrometry method was adapted from and validated according to the latest European Medicines Agency guidelines \[[@CR17]\]. The assay has a linear dynamic range of 1--50 ng/mL. Between-run and between-day imprecision (measured by a coefficient of variation) were within 10% and bias was under 3%. Low, median, and high controls were all within 15%. Furthermore, results over 5 years from an international inter-proficiency testing program for tacrolimus showed that all external quality controls were within 15%. The unbound tacrolimus concentrations were quantified using the Thermo Scientific (Waltham, MA, USA) Quantiva LC-MS/MS system with an Ultimate 3000 UHPLC.

Covariates {#Sec5}
----------

Clinical and laboratory data were collected for the study period for: sex, age, reason for transplantation, type of transplantation, length and bodyweight, the Sequential Organ Failure Assessment score, use of extracorporeal membrane oxygenation, administration of red blood cells, concentrations of hematocrit, albumin, high-density lipoproteins, α1-acid glycoprotein, and pH (see also Table [1](#Tab1){ref-type="table"} and Table S1 of the Electronic Supplementary Material \[ESM\]).Table 1Patient characteristicsCharacteristics*N* = 30Median (*Q*1; *Q*3)Male, *n* (%)15 (50)--Age, (years)--43 (34; 60)Bodyweight, (kg)--73.5 (61; 86)Length, (cm)--173.5 (169; 176)Reason for transplantation, *n* (%) Heart (*n* = 10) Ischemic CMP, *n* (%)5 (17)-- Non-ischemic CMP, *n* (%)5 (17)-- Lung (*n* = 20) Cystic fibrosis, *n* (%)10 (33)-- COPD, *n* (%)3 (10)-- IPAH, *n* (%)2 (7)-- Bronchectasis, *n* (%)1 (3)-- Sarcoidosis, *n* (%)1 (3)-- Langerhans cell histiocytosis, *n* (%)1 (3)-- Idiopathic pulmonary fibrosis, *n* (%)2 (7)-- Double lung transplantation, *n* (%)18 (90)--Parameters Ht^a^  Day 10.31 (0.28; 0.35)  Day 20.28 (0.25; 0.30)  Day 30.27 (0.25; 0.28)  Day 40.27 (0.25; 0.29)  Day 50.27 (0.24; 0.30)  Day 60.28 (0.27; 0.29) Alb^b^  Day 126.2 (22.5; 29.3) HDL^c^  Day 10.84 (0.70; 1.06) AAG^d^  Day 10.89 (0.76; 1.18) pH^e^  Day 17.39 (7.33; 7.43) Administration of packed red blood cells, (mL/day)  Day 1275 (275; 550) Postoperative ECMO frequency, *n* (%)8 (27) Postoperative ECMO duration, (days)4 (2; 6)*AAG* α1-acid glycoprotein, *Alb* albumin, *CMP* cardiomyopathy, *COPD* chronic obstructive pulmonary disease, *ECMO* extracorporeal membrane oxygenator, *HDL* high-density lipoprotein, *Ht* hematocrit, *IPAH* idiopatic pulmonary arterial hypertension, *Q* quartileNormal ranges: ^a^Ht; male 0.41--0.50, female 0.36--0.46^b^Alb: 35--50 g/L^c^HDL: male 0.90--1.70, female 1.10--2.00 mmol/L^d^AAG: 0.5--1.2 g/L^e^pH: 7.35--7.45

Population-Pharmacokinetic Analysis {#Sec6}
-----------------------------------

NONMEM version 7.3.0 was used for modeling tacrolimus pharmacokinetics. The Piraña software program version 2.9.4 was used as an interface for NONMEM and R for Windows version 3.3.1 was used to analyze the results.

Mixed-Effects Modeling {#Sec7}
----------------------

An open two-compartment linear model with first-order oral absorption best fitted the data. For some dosing occasions, zero order absorption was used. The structural model included the following parameters: clearance, inter-compartmental clearance, distribution volume *V*1 and *V*2, and absorption rate constant. The rate of binding of tacrolimus within the central compartment to red blood cells and proteins was considered to be much higher than distribution to the peripheral compartment and elimination. Therefore, whole-blood, total plasma, and unbound plasma concentrations were assumed to be in equilibrium all the time. To incorporate total and unbound plasma concentrations, models for linear binding kinetics (Eq. [1](#Equ1){ref-type=""}) and models for saturable binding equilibriums (Eq. [2](#Equ2){ref-type=""}) were tested:$$\documentclass[12pt]{minimal}
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Total plasma concentrations were similarly related to the unbound plasma concentrations. As tacrolimus is mainly bound to erythrocytes, hematocrit was introduced into the model by multiplying Nplasma or Bmax with the observed hematocrit with the last observation of hematocrit carried forward.Inter-individual variability and inter-occasion variability were described assuming a log normal distribution with the following equation:$$\documentclass[12pt]{minimal}
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                \begin{document}$$Cij = Cpredij \left( {1 + eij} \right),$$\end{document}$,where *C*~*ij*~ is the *i*th observation for the *j*th individual, *Cpred*~*ij*~ is the tacrolimus concentration predicted by the model, and *e*~*ij*~ is the difference between *C*~*ij*~ and Cpred~*ij*~. All values of *eij* were assumed to be normally distributed with mean 0 and standard deviation *σ*. Residual error was separately estimated for whole-blood, total, and unbound plasma concentrations. The correlation between these residual error components was estimated using the L2 data option of NONMEM.

The modeling process was performed using the stochastic approximation expectation maximization estimation method with interaction. The likelihood was subsequently established using the Monte Carlo importance sampling estimation method assisted by mode a posteriori. The parameter precision was estimated using the sampling importance resampling procedure \[[@CR18]\]. The values of concentrations below the lower limit of quantification were discarded (3.9%; 46 values out of 1180). Model diagnostics were performed by visual checks of standard diagnostic plots, i.e., 'goodness-of-fit' plots (see Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Goodness-of-fit plots of predicted unbound tacrolimus plasma concentrations

Pharmacokinetic Simulation {#Sec8}
--------------------------

The effect of hematocrit on unbound tacrolimus plasma concentrations was assessed by simulation of unbound plasma concentrations for different hematocrit values at a constant WBC (9 ng/mL) using final typical parameter estimates.

Statistical Analyses {#Sec9}
--------------------

Variables are presented as median (with the first and third quartiles), range, 95% confidence interval (95% CI), or number (proportion) where appropriate.

Results {#Sec10}
=======

Patient Characteristics {#Sec11}
-----------------------

Ten heart and twenty lung transplantation patients were enrolled in the study and completed the study protocol. Half of the patients were women (15 out of 30; 50%) and the median age was 43 years (range 34--60 years). All heart transplantation patients were diagnosed with dilated cardiomyopathy of whom five patients had ischemic cardiomyopathy and one patient was diagnosed with giant cell myocarditis. Reasons for lung transplantation were cystic fibrosis, chronic obstructive pulmonary disease, idiopathic pulmonary arterial hypertension, idiopathic pulmonary fibrosis, bronchiectasis, Langerhans cell histiocytosis, and sarcoidosis. In Table [1](#Tab1){ref-type="table"}, patient characteristics are summarized. For additional information on clinical characteristics, see Table S1 in the ESM.

Descriptive Pharmacokinetics {#Sec12}
----------------------------

The total number of whole-blood tacrolimus profiles over 0--12 h was 119 with a median of five profiles per patient (range 1--6 profiles). Ninety total and unbound plasma tacrolimus 0- to 12-h profiles were obtained with a median of three per patient (range 0--6). The whole-blood, total, and unbound plasma pharmacokinetic parameters are shown in Table [2](#Tab2){ref-type="table"}. The majority of tacrolimus was associated with erythrocytes as plasma concentrations were \< 1% of the whole-blood concentrations. Tacrolimus unbound fraction was \< 0.0001 in this population. In Fig. [2](#Fig2){ref-type="fig"}a, the observed relationship between unbound plasma and whole-blood concentrations is shown, suggesting non-linear binding of tacrolimus to erythrocytes. The total tacrolimus plasma concentrations showed a linear relationship with the unbound plasma concentrations (see Fig. [2](#Fig2){ref-type="fig"}b).Table 2Pharmacokinetic parametersObserved pharmacokineticsMedian (minimum--maximum)Unbound tacrolimus plasma concentrations *C*12h, (pg/mL)1.84 (0.42--11) *C*~max~, (pg/mL)2.97 (0.51--12.2) *T*~max~, (h)2.3 (1.2--14.0)Total plasma concentrations *C*12h, (pg/mL)282 (46--1373) *C*~max~, (pg/mL)403.5 (61--2640) *T*~max~, (h)2.25 (0.4--14.0)Whole-blood tacrolimus concentrations *C*12h, (ng/mL)9.5 (0.5--38.7) *C*~max~, (ng/mL)18.5 (2.1--74.7) *T*~max~, (h)1.6 (0.4--8.0)*C12h* concentration at 12 h after administration, *Cmax* maximum C12h, *Tmax* time to maximum concentrationFig. 2**a** Tacrolimus unbound plasma concentrations (UPC) vs. tacrolimus whole-blood concentrations (WBC). The figure shows a non-linear relationship between UPC and WBC. **b** UPC vs tacrolimus total plasma concentrations (TPC). The figure shows a linear relationship between UPC and TPC

Model Development {#Sec13}
-----------------

We used a two-compartmental model for whole-blood, total, and unbound plasma tacrolimus concentrations with mixed zero-order and first-order absorption (for a schematic illustration of the pharmacokinetic model, see Fig. [3](#Fig3){ref-type="fig"}). To reduce model complexity, the parameters related to absorption and the associated variability were fixed to the previously estimated values. Non-linear binding to erythrocytes and linear binding to plasma proteins best described the data. Furthermore, the Bmax to erythrocytes was directly proportional to hematocrit.Fig. 3Schematic representation of the population-pharmacokinetic whole-blood concentration (WBC) model for tacrolimus. The central compartment, with volume *V*1, is swiftly in equilibrium with the peripheral compartment represented by volume *V*2. Drug transfer between this peripheral compartment and the central compartment is described with the inter-compartmental clearance parameter *Q*. *k*~a~ is the absorption rate constant and CL is the whole-blood tacrolimus clearance. The unbound plasma concentration of tacrolimus (UPC) was computed using a non-linear model, as follows: UPC = (WBC × *kd*1)/(*B*max × Ht − WBC), where *kd1* is the dissociation constant (fitted parameter), *Bmax* is the maximum binding capacity (fitted parameter), and *Ht* is the observed hematocrit (last observation carried forward). The total plasma concentration (TPC) was computed using a linear model, as follows: *TPC* Nplasma × UPC with *Nplasma* non-specific binding constant for total plasma concentrations (fitted parameter)

Table [3](#Tab3){ref-type="table"} shows the parameter estimates and precision of the final model. The parameter precision was acceptable for all relevant parameters, as represented by the small 95% CI of the parameter estimates. The residual unexplained variability was low for the whole-blood concentrations at 16.7% (95% CI 15.8--17.6) and higher for the unbound concentrations at 36.3% (95% CI 33.9--40.4) and total plasma concentrations at 31.6% (95% CI 28.6--34.2). Substantial correlation of residual variability between whole-blood and plasma concentration was found as expected. Goodness-of-fit plots of unbound tacrolimus plasma concentrations exhibited widely dispersed data around the unity line.Table 3Final population-pharmacokinetic parameters with 95% confidence interval (CI) based on sampling importance resamplingParameterEstimated value (95% CI)IIV, (%) (95% CI)IOV, (%) (95% CI)CL, (L/h)20.9 (16.8--24.7)42.1 (30--60)*V*1, (L)220 (187--246)10 Fixed*K*~a~, (1/h)0.579 Fixed10 Fixed98.3 Fixed*Q*, (L/h)72.0 (529--767)10 Fixed*V*2, (L)469 (399--579)10 Fixed*B*max (WBC), (pg/mL)2700 (1750--3835)27 (19--36)*Kd* (WBC), (pg/mL)0.142 (0.087--0.195)3 FixedNplasma137 (120--152)29 (22--41)*F*1 Fixed10 Fixed65 (58--84)RUVSD-PE (95% CI)WBC16.7% (15.8--17.6)UPC36.3% (33.9--40.4)TPC31.6% (28.6--34.2)Correlation RUV (WBC, UPC and TPC)*R*R (WBC, UPC)0.26R (WBC, TPC)0.51R (UPC, TPC)0.51ParameterRange (minimum--maximum)AUC (WBC), (μg h/L)151.2 (31.2--2525)AUC (UPC), (ng h/L)266 (10--928)T1/2 (WBC), (h)9.4 (6.0--31.4)*AUC* area under the curve, *Bmax* maximum binding capacity, *IIV* inter-individual variability, *IOV* inter-occasional variability, *Cl* clearance, *F* bioavailability, *h* hours, *ka* absorption constant rate, *kd* diffusion constant rate, *Nplasma* total plasma to unbound plasma coefficient, *Q* inter-compartmental clearance, *R* correlation coefficient, *RUV* residual unexplained variability, *SD-PE* standard deviation point estimate, *T1/2* half-life, *TPC* total plasma concentration, *UPC* unbound plasma concentration, *V* distribution volume, *WBC* whole-blood concentration

Results of Pharmacokinetic Modeling and Simulations {#Sec14}
---------------------------------------------------

Large inter-occasion variability in bioavailability was found, which dominates inter-individual variability (see Table [3](#Tab3){ref-type="table"}). The dissociation constant of distribution to erythrocytes was estimated at 0.142 pg/mL (95% CI 0.087--0.195), which is relatively high and only indicates a slight non-linear distribution relevant at high tacrolimus concentrations. However, this model was superior to a linear binding model. The Nplasma for total plasma concentrations was estimated at 137 (95% CI 120--152), indicating that total plasma concentrations were typically 137-fold higher than unbound plasma concentrations. Moreover, the inter-individual variability in the binding constants was also considerable (27% for Bmax WBC and 29% for Nplasma).

Simulations of different hematocrit ratios ranging from 0.25 to 0.50 at a fixed WBC of 9 ng/mL were conducted. The unbound concentration decreased with increasing hematocrit and ranged from 1.06 to 2.14 pg/mL. When the hematocrit declined from 0.45 to 0.30, the unbound tacrolimus plasma concentration showed to be 1.5 times higher. A non-linear relationship between unbound plasma and hematocrit was observed as shown in Fig. [4](#Fig4){ref-type="fig"}.Fig. 4Simulations of different hematocrit values with a fixed whole-blood concentration of 9 ng/mL. On the *y*-axis, the unbound tacrolimus plasma concentrations are plotted against hematocrit

Discussion {#Sec15}
==========

This is the first report of a population-pharmacokinetic model of whole-blood, total, and unbound tacrolimus plasma concentrations. Accumulation of tacrolimus in erythrocytes was high relative to plasma concentrations. The whole-blood to unbound plasma concentration ratios differed with changes in hematocrit and showed saturation in the higher range of whole-blood tacrolimus concentrations. Consequently, the combination of high whole-blood tacrolimus concentrations with low hematocrit concentrations may result in extremely high unbound plasma concentrations and hence, in toxicity. From a theoretical perspective, the unbound tacrolimus plasma concentrations would be a better surrogate for the prediction of clinical outcomes. Yet, the analysis of unbound tacrolimus plasma concentrations is challenging and not easily standardized. As a linear relationship between total and unbound tacrolimus plasma concentrations was found, measurement of total plasma concentrations may be considered as an alternative predictive biomarker of clinical outcomes. However, the accuracy and precision of plasma tacrolimus concentration quantification are vulnerable to hemolysis of whole-blood samples. To circumvent these bio-analytical challenges, hematocrit-corrected whole-blood concentrations may be the most feasible and suitable surrogate for the prediction of clinical outcomes.

The whole-blood concentrations far exceeded total plasma concentrations, indicating that tacrolimus mainly distributes within erythrocytes. This is in line with earlier reports, although the plasma-to-blood ratio we found was considerably lower \[[@CR8], [@CR15], [@CR19]\]. We observed a large variability in unbound tacrolimus plasma concentrations. Moreover, the observed high inter-individual variability in the binding constants (Bmax WBC and Nplasma) indicates highly variable binding of tacrolimus in the central compartment. It has been shown that tacrolimus whole-blood apparent clearance is inversely correlated to hematocrit and erythrocyte count \[[@CR9], [@CR20]--[@CR22]\]. Although comparable with a study in pregnant women, we observed a low median and wide range in hematocrit in this population compared with studies after liver and kidney transplantation \[[@CR8], [@CR9], [@CR12], [@CR23]\]. This may be explained by frequent major bleedings peri-operatively, bone marrow depression due to inflammation, blood cell transfusions needed to optimize oxygen demand, and hemolysis due to the use of extracorporeal equipment, which are all common events in thoracic transplant patients in the early post-transplant phase. Moreover, we observed a non-linear relationship between whole-blood and unbound tacrolimus plasma concentrations suggesting saturation of erythrocytes. The relatively high dissociation constant indicates that binding to erythrocytes was only slightly non-linear in the observed unbound concentration range, which is substantiated by the relative large CI of this parameter. Although suggested by in vitro observations, saturation has never been observed in vivo before \[[@CR8], [@CR24], [@CR25]\]. A combination of high tacrolimus concentrations with low hematocrit concentrations may result in excessively high unbound concentrations and consequently lead to tacrolimus-related toxicity.

Interestingly, the Bmax of erythrocytes showed wide inter-patient variability. Different protein content within erythrocytes may explain this finding. Tacrolimus is bound to the cytoplasmic FK506 binding protein 12 and to a lesser extent to the membrane-associated FK506 binding protein 13 \[[@CR19], [@CR26]--[@CR28]\]. Saturation of these proteins within the erythrocyte is the most logical explanation for this effect \[[@CR28], [@CR29]\].

The simulation of unbound tacrolimus concentrations with different hematocrit and fixed WBC indicated that patients with a low hematocrit tend to have lower whole-blood concentrations, whilst the unbound concentration is around the population mean. In practice, transplant physicians will increase the dose, even though the unbound concentrations as well as the total plasma concentrations will increase as shown by our data. Increasing the dose may lead to higher toxicity by higher unbound concentrations. On the contrary, the risk for rejection is low early after lung transplantation while prevention from cellular and antibody-mediated rejection is also controlled with the addition of induction therapy with an interleukin-2 receptor antagonist, anti-thymocyte globulins, or anti-CD52 monoclonal antibodies next to triple therapy with corticosteroids, an anti-proliferative agent, and tacrolimus \[[@CR30]\]. However, a low WBC does not imply a low unbound plasma concentration. The simulation showed that a decline in hematocrit, e.g., from 0.45 to 0.30, indicates an increase in the unbound tacrolimus plasma concentrations from 1.15 up to 1.77 pg/mL, which is 1.5 times higher. For clinical practice, this could mean that, at a constant WBC of 9 ng/mL and a decline of hematocrit from 0.45 to 0.30, lowering the dose by 33% should be efficacious to control the unbound tacrolimus plasma concentration.

Importantly, sample procurement may highly influence unbound tacrolimus plasma concentrations. Swift analysis of the samples is important as well as incubation and centrifugation temperatures. Hemolysis may influence the plasma concentrations whilst no difference was found between analyses at 20 °C or 37 °C \[[@CR15], [@CR31], [@CR32]\]. In this study, blood samples were immediately centrifuged to minimize erythrocyte damage and tacrolimus distribution from red blood cells to plasma. Importantly, at lower temperatures (4 °C), affinity to erythrocytes is higher than at room and body temperatures \[[@CR31]\]. In this study, temperature was kept constant during centrifugation and subsequent filtration at 25 °C to diminish a temperature-dependent effect on the binding of tacrolimus to erythrocytes \[[@CR16]\]. This vulnerability to hemolysis makes analyses of plasma tacrolimus concentrations as a routine practice a major challenge. Our results concur with previous studies that suggest hematocrit-corrected whole-blood concentrations could be of use for improved target exposure \[[@CR11], [@CR24], [@CR33]\]. We assume that only correction to hematocrit is sufficient while protein levels will not have a large effect on the whole-blood concentrations because the majority of tacrolimus was associated with erythrocytes and plasma concentrations were \< 1% of the whole-blood concentrations. The advantage of monitoring hematocrit-corrected whole-blood concentrations over unbound or total plasma concentrations is that it may be easily implemented in daily transplantation practice.

The strong aspects of this study are the use of full 12-h profiles, the use of high-performance liquid chromatography with tandem mass spectrometry for analyses of tacrolimus concentrations, and the use of non-linear mixed-effects modeling for pharmacokinetic modeling. Earlier studies on unbound concentrations were mostly performed with immuno-assays, which in itself have large variations and may have unreliable results especially in the low range of the unbound concentrations \[[@CR7], [@CR9], [@CR34]\].

Although a relatively small group of patients was included, the number of tacrolimus profiles was sufficient to perform pharmacokinetic modeling. We did not examine any relationships between the pharmacokinetics and pharmacodynamics of unbound and total tacrolimus plasma concentrations in this study. Whether hematocrit-corrected dosing diminishes the variability in unbound plasma concentrations and subsequent toxicity needs further validation.

Conclusions {#Sec16}
===========

A two-compartment pharmacokinetic model was designed with mixed zero and first-order absorption of tacrolimus whole-blood, total, and unbound plasma concentrations in thoracic organ recipients in the first week after transplantation. The unbound concentration was mainly influenced by the variability in erythrocyte count. Erythrocyte binding was saturable. Subsequently, the total or unbound tacrolimus plasma concentrations might be better predictors of clinical outcomes. Nevertheless, robust bio-analysis of the unbound tacrolimus plasma as well as the total plasma concentrations is challenging. Therefore, hematocrit-corrected whole-blood concentrations may serve as the most feasible and suitable predictive exposure measure to improve clinical outcomes and should be further explored in future studies.
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